Ming Li
Endocrinology, Diabetes & Metabolism · San Jose, CANPI 1982702056
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.2% of the total across 176 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 16.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $998 and has fallen 82.5% since, to $175 in 2025.
Across 176 payments — averaging $21.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$628
- Novo Nordisk$473
- AstraZeneca$399
- Boehringer Ingelheim$358
- Sanofi-aventis U.S. LLC$343
- AbbVie$266
- plus $1K from 19 others
What the payments were for
- Food & beverage$3,77199%
- Education$321%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 28 | $628 |
| Novo Nordisk | 25 | $473 |
| AstraZeneca | 20 | $399 |
| Boehringer Ingelheim | 15 | $358 |
| Sanofi-aventis U.S. LLC | 17 | $343 |
| AbbVie | 14 | $266 |
| Johnson & Johnson(2 entities) | 9 | $203 |
| Regeneron Healthcare Solutions, Inc. | 6 | $182 |
| Merck | 7 | $154 |
| Amgen | 7 | $137 |
| Xeris Pharmaceuticals, Inc. | 5 | $104 |
| Dexcom, Inc. | 3 | $95 |
| Corcept Therapeutics | 4 | $94 |
| Kowa Pharmaceuticals America, Inc. | 3 | $69 |
| Legend Biotech USA Inc. | 2 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $51 |
| Pfizer | 1 | $27 |
| Genmab U.S., Inc. | 1 | $25 |
| Abbott | 1 | $23 |
| Blueprint Medicines Corporation | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| EUSA Pharma (US) LLC | 1 | $20 |
| Recordati_rare_diseases_inc. | 1 | $20 |
| Geron Corporation | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
How this compares
$3,803 in reported general payments places this provider in the 65th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Other endocrinology, diabetes & metabolism in San Jose
- Joselito CabaccanSan Jose$1.4M
- Archana BindraSan Jose$70K
- Juan FriasSan Diego$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.